Previous 10 | Next 10 |
NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression PR Newswire · The independent Data Safety Monitoring Board recommended continuation of patient...
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 PR Newswire RADNOR, Pa. , March 17, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ( Nasdaq: NRXP ) ("NRx Pharmaceuticals", the "Company"), a clin...
NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering PR Newswire NRx Pharmaceuticals received approximately $2.9 million in cash from existing investors. Offering will assist the Company to initiate its National Treatment Protocol and Safety D...
NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio PR Newswire Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in...
NRx Pharmaceuticals ( NASDAQ: NRXP ) on Monday reported the minutes of a Type B meeting with the U.S. Food and Drug Administration's (FDA) Division of Psychiatry Products held on Jan. 11 linked to filing of a new drug application (NDA) for NRX-101 for severe bipolar depression. The FD...
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality PR Newswire FDA discussed a broader indication of "treatment of recently acutely suicidal...
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior PR Newswire The Independent Data Safety Monitoring Board identified no safety concerns and iss...
Clinical-stage pharma NRX Pharmaceuticals ( NASDAQ: NRXP ) traded higher in the pre-market Thursday after announcing FDA comments on its plans to develop the lead candidate NRX-101 for suicidal bipolar depression. Citing FDA’s written responses on the program, NRX (NRX) said th...
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 PR Newswire RADNOR, Pa. , Jan. 19, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a c...
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference PR Newswire RADNOR, Pa. , Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasd...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...